Navigation Links
Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
Date:5/14/2013

comprises a group of individuals who have made significant contributions to the advancement of medical science, biotech entrepreneurship and the development of drugs serving unmet medical needs," said Sir Michael.  "ITI has set itself on a course to develop outstanding new pharmaceuticals to treat CNS diseases, surely an ambitious task, but one in which I am pleased to join and help."

ABOUT ITI-007

ITI-007 is the Company's first-in-class antipsychotic with a unique mechanism of action.  ITI-007 combines potent 5-HT2A receptor antagonism with dopamine receptor phosphoprotein modulation (DPPM) and serotonin reuptake inhibition for the treatment of acute and residual schizophrenia.  At dopamine D2 receptors, ITI-007 has dual properties acting as a post-synaptic antagonist and as a pre-synaptic partial agonist.  ITI-007 also stimulates phosphorylation of glutamatergic NMDA NR2B receptors in a mesolimbic specific manner.  This regional selectivity in brain areas thought to mediate the efficacy of antipsychotic drugs together with serotonergic, glutamatergic, and dopaminergic interactions is expected to result in superior antipsychotic efficacy for positive, negative, affective and cognitive symptoms associated with schizophrenia.  The serotonin reuptake inhibition allows for additional antidepressant efficacy for the treatment of schizoaffective disorder, co-morbid depression, and/or as a stand-alone treatment for major depressive disorder (MDD).  ITI-007 is currently in a Phase II clinical trial in schizophrenia.  We believe ITI-007 will be useful for the treatment of behavioral disturbances in dementia, autism and other CNS diseases and well as in bipolar disorder and other psychiatric and neurodegenerative disorders.

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of t
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
2. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
3. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
4. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
5. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
6. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
7. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
8. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
9. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
10. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
11. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... (PRWEB) May 28, 2015 DryLet, ... use in applications such as animal waste reduction, ... oil reduction in wastewater treatment plants and restaurant ... the World Pork Expo, June 3-5 in Des ... year in a Wall Street Journal article because ...
(Date:5/28/2015)... N.J. , May 28, 2015  PDS ... a cancer immunotherapy treatment targeting HPV-16, has generated ... Currently, pre-cervical cancer is treated by ... a simple and effective non-surgical alternative. Results show ... mechanisms (T-cells) to recognize, target, and kill precancerous ...
(Date:5/28/2015)... 2015 Biscayne Pharmaceuticals, Inc ., today ... growth hormone-releasing hormone (GHRH) technology will be discussed in a ... Meeting. The data show that the family of receptors ... is present on many primary breast cancer cells regardless ... antagonists could have broad anti-cancer potential in breast cancer. ...
(Date:5/28/2015)... and London (PRWEB) May 28, 2015 ... of Computer Aided Engineering software, announced today it ... Inc. (PSRI). CD-adapco will provide state-of-the-art engineering simulation ... will share their expertise and experiences in analyzing ... refining industry members and advance the understanding of ...
Breaking Biology Technology:DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... Ill., July 1 Healthation, a healthcare,technology ... large Canadian Third,Party Administrator (TPA) to a ... use,the integrated real-time, rules-based AcceleHealth(R) benefits and ... deliver interactive,self-service capabilities across its medical, dental, ...
... Mich., July 1 Neogen Corporation,(Nasdaq: NEOG ... product line used in,animal health and hygiene applications ... includes 14 different product formulations,along with manufacturing process ... terms were not disclosed., The addition of ...
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that ... present a,company update at the Collins Stewart Growth Conference ... 9:30 a.m. ET., Interested parties may access a ... of the BioMarin website, http://www.BMRN.com . A,replay of ...
Cached Biology Technology:Healthation Chosen by Large Canadian Third Party Administrator to Support All Employee Benefits and Claims Administration 2Neogen Acquires Product Line From DuPont Animal Health Solutions 2BioMarin to Present at the Collins Stewart Growth Conference 2
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... have found that the main source of food for many ... to adapt in order to survive climate change. Billions ... just a few millimetres in size, live in the waters ... It showed they responded to global warming after the ...
... Enhanced Recognition Capabilities for Use in ... and Computer Vision Applications, VILNIUS, ... ), a provider of high-precision biometric,and ... availability of,SentiSight 2.0 SDK universal object ...
... First Such Board on the Market, Stantum,s SMK ... Their Own Resistive Multi-Touch Applications, SAN DIEGO, ... pioneer developer of multi-touch sensing,technology, today introduced a ... PMatrix(TM) resistive multi-touch technology, which lets,users simultaneously move ...
Cached Biology News:Researchers find animal with ability to survive climate change 2Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology 2Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology 3Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology 2
Leucine-rich repeat-containing G-protein coupled receptor 4...
WD-repeat protein 4...
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
... Cultured human omental preadipocytes ... but otherwise healthy donors. ... of diabetic cells. Please ... Support media also available. ...
Biology Products: